Metabolic Dysfunction-Associated SteatoHepatitis
Conditions
Interventions
High HOMA2-IR group:None
Low HOMA2-IR group:None
Sponsors
The First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: This study plans to enroll patients aged =18 years with a confirmed diagnosis of type 2 diabetes mellitus (duration =6 months) and imaging-confirmed hepatic steatosis, who also meet at least two of the non-invasive "high-risk MASH" criteria (including elevated ALT, FIB-4 >1.3, BMI =25 kg/m², triglycerides =1.7 mmol/L, or imaging evidence of moderate to severe fatty liver).
Exclusion criteria
Exclusion criteria: clearly defined liver diseases (such as viral hepatitis, alcoholic liver disease, autoimmune liver disease, etc.); severe systemic comorbidities (e.g., advanced cirrhosis, malignant tumors, end-stage renal disease, severe heart failure); use of medications that may affect hepatic fat metabolism within the past 3 months (including GLP-1 receptor agonists, PPAR? agonists, high-dose vitamin E, etc.); pregnancy or lactation; current participation in other interventional clinical trials; or missing >20% of key baseline or follow-up data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum ALT levels;Serum AST level;Platelet count;Fasting plasma glucose;Fasting triglyceride;Age;Body weight;Height; | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting C-peptide; | — |
Countries
China
Contacts
Public ContactGuoli Du
The First Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed